These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 14968122

  • 1. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
    Miller SR, Sekijima Y, Kelly JW.
    Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
    [Abstract] [Full Text] [Related]

  • 2. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
    Green NS, Foss TR, Kelly JW.
    Proc Natl Acad Sci U S A; 2005 Oct 11; 102(41):14545-50. PubMed ID: 16195386
    [Abstract] [Full Text] [Related]

  • 3. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
    Tojo K, Sekijima Y, Kelly JW, Ikeda S.
    Neurosci Res; 2006 Dec 11; 56(4):441-9. PubMed ID: 17028027
    [Abstract] [Full Text] [Related]

  • 4. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y, Dendle MT, Wiseman RL, White JT, D'Haeze W, Kelly JW.
    Amyloid; 2006 Jun 11; 13(2):57-66. PubMed ID: 16911959
    [Abstract] [Full Text] [Related]

  • 5. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR, Powers ET, Kelly JW.
    Biochemistry; 2008 Jul 01; 47(26):6969-84. PubMed ID: 18537267
    [Abstract] [Full Text] [Related]

  • 6. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
    Zhang Q, Kelly JW.
    Biochemistry; 2005 Jun 28; 44(25):9079-85. PubMed ID: 15966731
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS, Palaninathan SK, Sacchettini JC, Kelly JW.
    J Am Chem Soc; 2003 Nov 05; 125(44):13404-14. PubMed ID: 14583036
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA, Lai Z, Kelly JW.
    Biochemistry; 1998 Dec 22; 37(51):17851-64. PubMed ID: 9922152
    [Abstract] [Full Text] [Related]

  • 9. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colón W.
    Biochemistry; 1995 Oct 17; 34(41):13527-36. PubMed ID: 7577941
    [Abstract] [Full Text] [Related]

  • 10. Cooperative stabilization of transthyretin by clusterin and diflunisal.
    Greene MJ, Klimtchuk ES, Seldin DC, Berk JL, Connors LH.
    Biochemistry; 2015 Jan 20; 54(2):268-78. PubMed ID: 25478940
    [Abstract] [Full Text] [Related]

  • 11. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM.
    Proc Natl Acad Sci U S A; 2013 Jun 11; 110(24):9992-7. PubMed ID: 23716704
    [Abstract] [Full Text] [Related]

  • 12. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
    Sekijima Y, Hammarström P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW.
    Lab Invest; 2003 Mar 11; 83(3):409-17. PubMed ID: 12649341
    [Abstract] [Full Text] [Related]

  • 13. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
    Zhang Q, Kelly JW.
    Biochemistry; 2003 Jul 29; 42(29):8756-61. PubMed ID: 12873136
    [Abstract] [Full Text] [Related]

  • 14. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
    Wiseman RL, Green NS, Kelly JW.
    Biochemistry; 2005 Jun 28; 44(25):9265-74. PubMed ID: 15966751
    [Abstract] [Full Text] [Related]

  • 15. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
    Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ.
    Biochem J; 2004 Jul 15; 381(Pt 2):351-6. PubMed ID: 15080795
    [Abstract] [Full Text] [Related]

  • 16. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW.
    Acc Chem Res; 2005 Dec 15; 38(12):911-21. PubMed ID: 16359163
    [Abstract] [Full Text] [Related]

  • 17. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T, Ando Y, Susuki S, Mikami F, Ikemizu S, Nakamura M, Suhr O, Anraku M, Kai T, Suico MA, Shuto T, Mizuguchi M, Yamagata Y, Kai H.
    FEBS Lett; 2006 Jan 23; 580(2):491-6. PubMed ID: 16386248
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.
    Yokoyama T, Mizuguchi M.
    Biol Pharm Bull; 2018 Jan 23; 41(7):979-984. PubMed ID: 29962408
    [Abstract] [Full Text] [Related]

  • 19. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
    Liang Y, Ore MO, Morin S, Wilson DJ.
    Biochemistry; 2012 Apr 24; 51(16):3523-30. PubMed ID: 22482799
    [Abstract] [Full Text] [Related]

  • 20. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
    Sekijima Y, Dendle MA, Kelly JW.
    Amyloid; 2006 Dec 24; 13(4):236-49. PubMed ID: 17107884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.